Cheaper Tuberculosis Drug Prices Offered by J&J and Lupin to Benefit Lower-Income Countries

In a significant development, pharmaceutical giants Johnson & Johnson (J&J) and Lupin, an Indian drug manufacturer, have decided to supply their versions of the tuberculosis drug bedaquiline at notably reduced prices in low- and middle-income nations. The announcement came from the global anti-tuberculosis group, the Stop TB Partnership, on Wednesday.

J&J's revised price of $130 and Lupin's price of $194 for a six-month treatment course represent a substantial reduction of 55% and 33% respectively, according to the United Nations-backed Stop TB Partnership.

Bedaquiline is among the few new drugs created to combat tuberculosis (TB) in over fifty years and plays a pivotal role in recommended treatment procedures for drug-resistant TB infections.

Atul Gawande, Assistant Administrator of the United States Agency for International Development's Global Health Bureau, expressed, "This remarkable price cut will broaden access to this life-saving medication and keep us on track to eliminate TB by 2030."

The availability of the drug at these lower prices will be facilitated through the Stop TB Partnership's Global Drug Facility, which serves as the primary procurer of TB treatments.

Positive Response to Lower Prices for Bedaquiline

J&J, known for marketing bedaquiline under the name Sirturo, entered an agreement with the Stop TB Partnership in July. This agreement allows the coalition to distribute generic versions of the drug through the Global Drug Facility.

This decision followed criticism from advocacy groups and author John Green, who questioned the pharmaceutical company's choice to uphold patents on the drug in multiple countries. J&J contested these allegations, asserting that their patents do not hinder access to the drug.

Doctors Without Borders, also known as Médecins Sans Frontières (MSF), welcomed the substantial price reduction, acknowledging that it "finally brings the price closer to the estimated generic price of $0.50 per day."

Nevertheless, J&J could further expand access to the drug by retracting its secondary patents on bedaquiline across countries with high TB burdens. Christophe Perrin, TB advocacy pharmacist with MSF's Access Campaign, suggested this course of action.